A modified weekly docetaxel schedule as first-line chemotherapy in elderly metastatic breast cancer: A safety study

Journal of Chemotherapy

Volumn 17, Issue 2, 2005, Pages 242-246

  Maisano, R ^a   Mare, M ^a   Caristi, N ^a   Chiofalo, G ^a   Picciotto, M ^a   Carboni, R ^a   Mafodda, A ^a   La Torre, F ^a  

^a UNIVERSITY OF MESSINA   (Italy)

Author keywords

Docetaxel; Elderly breast cancer patients; Metastatic breast cancer; Weekly docetaxel

Indexed keywords

DEXAMETHASONE; DOCETAXEL;

AGED; AGING; ALOPECIA; ANEMIA; ARM; ARTICLE; ASTHENIA; BREAST CANCER; BREAST METASTASIS; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG SAFETY; DYSGEUSIA; EPIPHORA; EPISTAXIS; FATIGUE; HUMAN; NAIL BED; NAIL COLOR DEFECT; NAIL DISEASE; NEUTROPENIA; PLEURA EFFUSION; RASH; SIDE EFFECT; SKIN EXFOLIATION; SKIN TOXICITY;

EID: 19544373257     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2005.17.2.242     Document Type: Article

References (22)

1. Linchtman SM. Guidelines for the treatment of elderly cancer patient. Cancer Control 2003; 10: 445-453.
2. Extermann M. Management issues for elderly patients with breast cancer. Curr Treat Options Oncol 2004; 5: 161-169.
3. Chan S, Friedrichs K, Noel D et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. The 303 Study Group. J Clin Oncol 1999; 17: 2341-2354.
4. Nabholtz JM, Senn HJ, Bezwoda WR et al. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. J Clin Oncol 1999; 17: 1413-1424.
5. Sjostrom J, Blomqvist C, Mouridsen H et al. Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group. Eur J Cancer 1999; 35: 1194-1201.
6. Bonneterre J, Roche H, Monnier A et al. Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure. Br J Cancer 2002; 87(11):1210-1215.
7. O'Brien MER, Leonard RCF, Barrett-Lee PJ et al. Docetaxel in the community setting: An analysis of 377 breast cancer patients treated with docetaxel (Taxotere) in the UK. Ann Oncol 1999; 10: 205-210.
8. Burstein HJ, Manola J, Younger J et al. Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol 2000; 18: 1212-1219.
9. Hainsworth JD, Burris HA, Yardley DA et al. Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: a Minnie Pearl Cancer Research Network phase II trial. J Clin Oncol 2001;19: 3500-3505.
10. Stemmler HJ, Gutschow K, Sommer H et al. Weekly docetaxel (Taxotere) in patients with metastatic breast cancer. Ann Oncol 2001; 12: 1393-1398.
11. Aihara T, Kim Y, Takatsuka Y. Phase II study of weekly docetaxel in patients with metastatic breast cancer. Ann Oncol 2002; 13: 286-292.
12. Maisano R, Mare M, Zavettieri M et al. Is weekly docetaxel an active and gentle chemotherapy in the treatment of metastatic breast cancer? Anticancer Res 2003; 23:1923-1926.
13. National Cancer Institute: Common toxicity criteria, version 2.0, 1999.
14. Miller AB, Hoogstroten B, Staquet M et al. Reporting results of cancer treatment. Cancer 1981; 47: 207-214.
15. Simon R. Optimal two-stage designs for phase II clinical trials. Contr Clin Trials 1989; 10: 1-10.
16. Newman RA, Amir Ahmadi M, Rivera E et al. Identification of docetaxel in tears from patients with metastatic breast cancer. Proc Am Soc Clin Oncol 2002; 21: 65 a, (abstr. 256).
17. Esmaeli B, Hortobagyi G N, Estava F et al. Canalicular stenosis secondary to weekly docetaxel: a potentially preventable side effect. Ann Oncol 2002; 13: 218-221.
18. Flory SM, Solimando DA Jr, Webster GF et al. Onycholisis associated with weekly administration of paclitaxel. Ann Pharmacother 1999; 33: 584-586.
19. Correia O, Azevedo C, Pinto Ferreira E et al. Nail changes secondary to docetaxel (Taxotere). Dermatology 1999; 198: 288-290.
20. Wasner G, Hilipert F, Baron R, Pfister J. Clinical pic sture: Nail changes secondary to docetaxel. Lancet 2001; 357: 910.
21. Spadaro P, Maisano R, Mare M et al. Is there correlation between decreased serum vascular endothelial growth factor (sVEGF) levels and nail toxicity in responsive metastatic breast cancer (MBC) patients treated with weekly docetaxel? Preliminary data of a phase II study. Proc Am Soc Clin Oncol 2002; 21: 35 b, (abstr. 1952).
22. Hussain S, Anderson DN, Salvatti ME et al. Onycholysis as a complication of systemic chemotherapy. Cancer 2000; 88: 2367-2371.